{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tamoxifen",
    "query": {
      "condition": "Tamoxifen"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 146,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tamoxifen&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T06:21:40.815Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00038103",
      "title": "Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib + Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 111,
      "start_date": "2002-01",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2010-02-25",
      "last_synced_at": "2026-06-11T06:21:40.815Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00038103"
    },
    {
      "nct_id": "NCT06361940",
      "title": "Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Aromatase inhibitors or tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2024-09-30",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-06-11T06:21:40.815Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06361940"
    },
    {
      "nct_id": "NCT00232661",
      "title": "PROACT - Pre-Operative Arimidex Compared To Tamoxifen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ARIMIDEX (anastrazole)",
          "type": "DRUG"
        },
        {
          "name": "NOLVADEX (tamoxifen)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "60 Years and older · Female only"
      },
      "enrollment_count": 452,
      "start_date": "2000-08",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2010-02-03",
      "last_synced_at": "2026-06-11T06:21:40.815Z",
      "location_count": 13,
      "location_summary": "Santa Rosa, California • New Britain, Connecticut • Torrington, Connecticut + 10 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Torrington",
          "state": "Connecticut"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Mason City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00232661"
    },
    {
      "nct_id": "NCT00710970",
      "title": "Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urinary Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seth Lerner",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2007-01",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-06-11T06:21:40.815Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00710970"
    },
    {
      "nct_id": "NCT00026286",
      "title": "Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Hot Flashes",
        "Menopausal Symptoms"
      ],
      "interventions": [
        {
          "name": "conjugated estrogens",
          "type": "DRUG"
        },
        {
          "name": "medroxyprogesterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": null,
      "start_date": "2000-11-28",
      "completion_date": "2007-06-15",
      "has_results": false,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-06-11T06:21:40.815Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Decatur, Illinois + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00026286"
    },
    {
      "nct_id": "NCT02979301",
      "title": "Impact of Low-dose Tamoxifen on BPU",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "High Background Uptake on MBI"
      ],
      "interventions": [
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2017-03-01",
      "completion_date": "2018-11-01",
      "has_results": true,
      "last_update_posted_date": "2019-07-16",
      "last_synced_at": "2026-06-11T06:21:40.815Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02979301"
    },
    {
      "nct_id": "NCT05774951",
      "title": "A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer, Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Camizestrant",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 4300,
      "start_date": "2023-03-31",
      "completion_date": "2036-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-06-11T06:21:40.815Z",
      "location_count": 126,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Anchorage, Alaska + 110 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05774951"
    },
    {
      "nct_id": "NCT00293540",
      "title": "Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "oophorectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "International Breast Cancer Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 249,
      "start_date": "2006-02",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-07-27",
      "last_synced_at": "2026-06-11T06:21:40.815Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00293540"
    },
    {
      "nct_id": "NCT00002920",
      "title": "S9630, Medroxyprogesterone in Treating Women With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "medroxyprogesterone",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 313,
      "start_date": "1997-03",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2012-10-31",
      "last_synced_at": "2026-06-11T06:21:40.815Z",
      "location_count": 122,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 84 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002920"
    },
    {
      "nct_id": "NCT06434064",
      "title": "Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Locally Advanced Unresectable Triple-Negative Breast Carcinoma",
        "Metastatic Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-03-03",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-06-11T06:21:40.815Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06434064"
    }
  ]
}